Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27 kip1 via the ERK signal pathway

Chinese Medical Journal

Volumn 124, Issue 19, 2011, Pages 3098-3104

  Liu, Ai Jun ^a   Ling, Feng ^a   Wang, Dong ^a   Wang, Qiang ^a   Lü, Xiao Dong ^a   Liu, Ying Long ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Extracellular signalregulated kinase; Fasudil; Human pulmonary smooth muscle cell; P27 kip1; Proliferation; Rho kinase

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; FASUDIL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; PLATELET DERIVED GROWTH FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NITROBLUE TETRAZOLIUM TEST; PROTEIN EXPRESSION; PULMONARY ARTERY; SMOOTH MUSCLE FIBER;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; UP-REGULATION;

EID: 80053464564     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.19.027     Document Type: Article

References (37)

1. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl): 25S-32S.
2. Yildiz P. Molecular mechanisms of pulmonary hypertension. Clin Chim Acta 2009; 403: 9-16.
3. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
4. Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H, et al. Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 2010; 55: 39-48.
5. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
6. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
7. kip1) is important in modulating pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol 2001; 25: 652-658.
8. kip1-independent pathway. Circ Res 2003; 92: 501-509.
9. kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000; 101: 2022-2025.
10. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
11. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
12. Barman SA, Zhu S, White RE. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc Health Risk Manag 2009; 5: 663-671.
13. Kamiyama M, Utsunomiya K, Taniguchi K, Yokota T, Kurata H, Tajima N, et al. Contribution of RhoA and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb 2003; 10: 117-123.
14. Chen XY, Dun JN, Miao QF, Zhang YJ. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine- induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 2009; 83: 67-79.
15. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108: 1640-1645.
16. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000; 101: 2030-2033.
17. Kanda T, Hayashi K, Wakino S, Homma K, Yoshioka K, Hasegawa K, et al. Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension 2005; 45: 724-729.
18. Cogolludo A, Moreno L, Villamor E. Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy. Pharmacology 2007; 79: 65-75.
19. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. Tohoku J Exp Med 2007; 211: 309-320.
20. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391-392.
21. Li FH, Xia W, Li AW, Zhao CF, Sun R. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin Med J 2007; 120: 22-29.
22. Ziino AJ, Ivanovska J, Belcastro R, Kantores C, Xu EZ, Lau M, et al. Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia. Pediatr Res 2010; 67: 177-182.
23. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004; 287: L656-L664.
24. Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 2004; 5: 355-366.
25. Zubiaur M, Sancho J, Terhorst C, Faller DV. A small GTP-binding protein, Rho, associates with the platelet-derived growth factor type-beta receptor upon ligand binding. J Biol Chem 1995; 270: 17221-17228.
26. Akiyama N, Naruse K, Kobayashi Y, Nakamura N, Hamada Y, Nakashima E, et al. High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor-beta increases migration of aortic smooth muscle cells. J Mol Cell Cardiol 2008; 45: 326-332.
27. Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999; 274: 37385-37390.
28. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002; 12: 9-18.
29. Matsumoto T, Yokote K, Tamura K, Takemoto M, Ueno H, Saito Y, et al. Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem 1999; 274: 13954-13960.
30. Davis W, Stephens LR, Hawkins PT, Saklatvala J. Synergistic activation of JNK/SAPK by interleukin-1 and platelet-derived growth factor is independent of Rac and Cdc42. Biochem J 1999; 338 (Pt 2): 387-392.
31. Zuckerbraun BS, Shapiro RA, Billiar TR, Tzeng E. Rho A influences the nuclear localization of extracellular signal-regulated kinases to modulate p21Waf/Cip1 expression. Circulation 2003; 108: 876-881.
32. Rice AB, Ingram JL, Bonner JC. p38 Mitogen-activated protein kinase regulates growth factor-induced mitogenesis of rat pulmonary myofibroblasts. Am J Respir Cell Mol Biol 2002; 27: 759-765.
33. kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells. J Biol Chem 2001; 276: 34958-34965.
34. Weber JD, Hu W, Jefcoat SC Jr, Raben DM, Baldassare JJ. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 1997; 272: 32966-32971.
35. kip1). J Biol Chem 1999; 274: 21926-21931.
36. Vidal A, Millard SS, Miller JP, Koff A. Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J Biol Chem 2002; 277: 16433-16440.
37. Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998; 17: 2393-2402.